If you remember one thingScore the liver before you pick the drug: every first-line trial enrolled only Child-Pugh A.
Child-Pugh A, no jaundice, ascites or encephalopathy?
no
Outside the trialsDecide with hepatology.
yes
Endoscopy in the last 6 months, varices treated?
yes
Atezolizumab + bevacizumab
not yet
Durvalumab + tremelimumab, or nivolumab + ipilimumabNo bevacizumab, no endoscopy gate.
- Child-Pugh: A is 5 to 6 points, B 7 to 9, C 10 or more.
- Tumor thrombus enhances like the mass: it is cancer, not clot. Heparin does not treat it.
- Main portal trunk was excluded from REFLECT and HIMALAYA; a branch was allowed.
Memory tricks
ABCDE = Albumin, Bilirubin, Clotting, Distension (ascites), Encephalopathy.
B for bevacizumab, B for bleeding: scope first.
STRIDE = Single Tremelimumab, Regular Interval Durvalumab.
Sources
Retrieved from PubMed, read on Nov 5, 2026.
- Finn RS, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma (IMbrave150). N Engl J Med 2020. doi:10.1056/NEJMoa1915745
- Abou-Alfa GK, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (HIMALAYA). NEJM Evid 2022. doi:10.1056/EVIDoa2100070
- Yau T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW). Lancet 2025. doi:10.1016/S0140-6736(25)00403-9